U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Homeocare Laboratories, Inc. - 521717 - 06/25/2018
  1. Warning Letters

CLOSEOUT LETTER

Homeocare Laboratories, Inc. MARCS-CMS 521717 —

Recipient:
Homeocare Laboratories, Inc.

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

 
 
Division of Pharmaceutical Quality Operations I
10 Waterview Blvd, 3rd FL
Parsippany, NJ 07054
Telephone: (973) 331-4900
FAX: (973) 331-4969 

CERTIFIED MAIL
RETURN RECIPT REQUESTED

June 25, 2018

Edith Scheiner, President
HomeoCare Labs Inc.
7 Odell Plaza, Suite 142-146
Yonkers, NY 10701

Dear Ms. Scheiner:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (CMS # 521717) dated September 7, 2017. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Yvette Johnson, Compliance Officer
Office of Pharmaceutical Quality Operations, Division I
Philadelphia District Office 

Back to Top